BioVie Inc.

NasdaqCM BIVI

BioVie Inc. Dividend Yield on January 14, 2025: 0.00%

BioVie Inc. Dividend Yield is 0.00% on January 14, 2025, a 0.00% change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

BioVie Inc. 52-week high Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
BioVie Inc. 52-week low Dividend Yield is 0.00% on January 14, 2025, which is 0.00% below the current Dividend Yield.
BioVie Inc. average Dividend Yield for the last 52 weeks is 0.00%.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

NasdaqCM: BIVI

BioVie Inc.

CEO	Mr. Cuong Viet Do M.B.A.
IPO Date	Sept. 18, 2020
Location	United States
Headquarters	680 West Nye Lane
Employees	14
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Key trends

Past 5 years